GO:0050431 transforming growth factor beta binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050431 (transforming growth factor beta binding) is a molecular function describing the binding of TGF-beta ligands to their receptors and binding proteins.
• TGF-beta binding is the first step in a signaling cascade that controls proliferation, differentiation, and extracellular matrix production in many cell types.
• Latent TGF-beta complexes require activation by binding proteins such as thrombospondin and proteoglycans before receptor engagement.
• Dysregulated TGF-beta binding contributes to fibrosis, chronic renal failure, and cancer progression.
• Key genes mediating TGF-beta binding include TGFBR1, TGFBR2, LTBP1, and decorin, which are frequent targets for CRISPR knockout and knock-in studies.
• CRISPR-based models (KO, point mutation, knock-in, overexpression) enable precise dissection of TGF-beta binding affinity and downstream signaling in disease contexts.
Description
Transforming growth factor beta (TGF-beta) is a multifunctional cytokine that regulates cell proliferation, differentiation, migration, and apoptosis. The molecular function defined by GO:0050431, transforming growth factor beta binding, encompasses the physical interaction between TGF-beta ligands and their cognate binding partners, including cell surface receptors and secreted binding proteins. This binding event is the initiating step for a broad range of physiological and pathological processes, from wound healing to fibrosis and cancer. Understanding the specificity and regulation of TGF-beta binding is therefore central to both basic cell biology and therapeutic development. Researchers study this function using biochemical binding assays, receptor affinity measurements, and genetic models that alter the expression or structure of TGF-beta ligands and their receptors. The QuickGO definition for GO:0050431 states: Binding to TGF-beta, transforming growth factor beta, a multifunctional peptide that controls proliferation, differentiation and other functions in many cell types. This definition underscores the dual role of TGF-beta binding in normal tissue homeostasis and in disease when dysregulated.
transforming growth factor beta binding At A Glance
| GO ID | GO:0050431 |
|---|---|
| GO term | transforming growth factor beta binding |
| Ontology | molecular_function |
| Synonym | TGF-beta binding; TGFbeta binding; transforming growth factor beta ligand binding to type II receptor; transforming growth factor beta ligand binding to type I receptor |
| Major function | Binding to TGF-beta, a multifunctional peptide that controls proliferation, differentiation and other functions in many cell types |
| Definition source | QuickGO |
| Related processes | TGF-beta signaling pathway, extracellular matrix organization, wound healing, fibrosis, cancer progression |
| Representative genes | TGFBR1, TGFBR2, TGFBR3, LTBP1, LTBP2, LTBP3, LTBP4, DCN, BGN, THBS1, ITGB6, ITGB8 |
What Is GO:0050431?
GO:0050431, transforming growth factor beta binding, is a molecular function term that describes the selective interaction of a protein or proteoglycan with TGF-beta. This binding can occur at the cell surface, as with TGF-beta type I and type II receptors, or in the extracellular matrix, as with latent TGF-beta binding proteins and proteoglycans. The term includes binding to both active and latent forms of TGF-beta, and it is a prerequisite for downstream signaling or for sequestration and activation of the ligand.
Why Is transforming growth factor beta binding Important in Cell Biology?
TGF-beta binding is a critical control point in cell signaling because it determines whether cells respond to TGF-beta or sequester it in latent complexes. Dysregulated TGF-beta binding is implicated in a wide range of diseases, including fibrosis, chronic renal failure, and cancer, making it a prime target for therapeutic intervention. Moreover, the binding affinity and specificity of TGF-beta to its receptors and binding proteins influence the duration and intensity of downstream signaling, which affects cell fate decisions.
• Controls cell proliferation and differentiation in many tissues.
• Regulates extracellular matrix production and wound healing.
• Dysregulation leads to fibrosis in kidney, lung, and skin.
• Involved in cancer progression and metastasis.
• Latent TGF-beta activation requires binding to thrombospondin and proteoglycans.
• Binding proteoglycans such as decorin modulate TGF-beta bioavailability.
• TGF-beta binding to type I and type II receptors initiates SMAD signaling.
• Genetic variants in TGF-beta binding proteins are associated with connective tissue disorders.
• Target for anti-fibrotic and anti-cancer therapeutics.
• Essential for immune regulation and tolerance.
Molecular Mechanism of transforming growth factor beta binding
Ligand recognition and receptor engagement
In simple terms: TGF-beta binds to its receptors on the cell surface like a key fitting into a lock.
TGF-beta ligands, including TGF-beta1, TGF-beta2, and TGF-beta3, are secreted as latent complexes. Upon activation, they bind to the extracellular domain of TGF-beta type II receptor (TGFBR2), which then recruits and phosphorylates type I receptor (TGFBR1). This binding event is highly specific and is the first step in the canonical SMAD signaling pathway.
Latent complex formation and activation
In simple terms: TGF-beta is often stored in a latent form that must be unlocked before it can bind receptors.
Latent TGF-beta binding proteins (LTBPs) covalently bind to the latency-associated peptide (LAP) of TGF-beta, forming large latent complexes in the extracellular matrix. Activation can be triggered by thrombospondin-1, which binds to LAP and induces a conformational change that releases active TGF-beta. Proteoglycans such as decorin also bind TGF-beta and can either sequester or present it to receptors.
Binding proteoglycans and co-receptors
In simple terms: Other proteins can grab TGF-beta and influence how much is available to signal.
Betaglycan (TGFBR3) is a proteoglycan that binds TGF-beta and presents it to TGFBR2, enhancing signaling. Decorin and biglycan are small leucine-rich proteoglycans that bind TGF-beta and neutralize its activity, thereby regulating matrix deposition. These interactions demonstrate the complexity of TGF-beta binding in the extracellular milieu.
Regulation of binding affinity and specificity
In simple terms: Cells can change how strongly TGF-beta binds by altering receptor levels or post-translational modifications.
The expression levels of TGFBR1 and TGFBR2 are regulated by transcriptional and post-transcriptional mechanisms, affecting binding capacity. Additionally, integrins such as alphaVbeta6 and alphaVbeta8 can bind to the RGD motif in LAP and activate TGF-beta, linking binding to mechanical cues. Phosphorylation of receptors can also modulate binding affinity and downstream signaling.
Downstream signaling initiation
In simple terms: Once TGF-beta binds, it switches on a chain of signals inside the cell.
Upon TGF-beta binding, TGFBR2 phosphorylates TGFBR1, which then phosphorylates SMAD2 and SMAD3. These form complexes with SMAD4 and translocate to the nucleus to regulate gene expression. This pathway controls diverse cellular responses, including growth arrest, differentiation, and apoptosis.
Key Genes Involved in GO:0050431 transforming growth factor beta binding
The following genes encode proteins that directly bind TGF-beta or regulate its binding, and they are frequently studied using CRISPR-based approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFBR1 | Type I receptor for TGF-beta; binds ligand after TGFBR2 recruitment | Knockout causes loss of TGF-beta signaling; point mutations linked to cancer |
| TGFBR2 | Type II receptor; primary high-affinity binder of TGF-beta | Frequent target for KO and knock-in to study binding affinity |
| TGFBR3 | Betaglycan; proteoglycan co-receptor that enhances TGF-beta binding to TGFBR2 | Modulates ligand presentation; KO reduces signaling in some cell types |
| LTBP1 | Latent TGF-beta binding protein 1; forms latent complexes in ECM | Knockout alters TGF-beta bioavailability and fibrosis |
| LTBP2 | Latent TGF-beta binding protein 2; regulates ligand sequestration | Mutations associated with connective tissue disorders |
| LTBP3 | Latent TGF-beta binding protein 3; involved in skeletal development | KO models show impaired TGF-beta activation |
| LTBP4 | Latent TGF-beta binding protein 4; protects against TGF-beta overactivation | Knockout increases fibrosis in muscle |
| DCN | Decorin; small proteoglycan that binds and neutralizes TGF-beta | Overexpression reduces fibrosis; KO increases TGF-beta activity |
| BGN | Biglycan; binds TGF-beta and modulates matrix assembly | KO affects bone and skin homeostasis |
| THBS1 | Thrombospondin-1; activates latent TGF-beta by binding LAP | KO impairs TGF-beta activation in wound healing |
| ITGB6 | Integrin alphaVbeta6; binds LAP and activates TGF-beta | KO reduces fibrosis in lung and kidney |
| ITGB8 | Integrin alphaVbeta8; activates TGF-beta in immune cells | KO affects immune tolerance |
| SMAD2 | Downstream effector phosphorylated upon TGF-beta binding | KO disrupts signaling; used to study pathway specificity |
| SMAD3 | Downstream effector; mediates transcriptional responses | KO mice develop colitis and cancer |
| SMAD4 | Common SMAD; forms complexes with SMAD2/3 | KO abolishes canonical TGF-beta signaling |
| FURIN | Proprotein convertase; processes pro-TGF-beta to latent form | KO impairs TGF-beta secretion |
| BMP1 | Metalloprotease; cleaves LTBP and releases TGF-beta | KO affects TGF-beta activation in bone |
How Is transforming growth factor beta binding Regulated?
TGF-beta binding is regulated at multiple levels. The expression of TGF-beta receptors and binding proteins is controlled by transcription factors and microRNAs. Extracellular matrix components, such as thrombospondin-1 and integrins, modulate the release of active TGF-beta from latent complexes. Additionally, post-translational modifications of receptors, including phosphorylation and ubiquitination, affect binding affinity and receptor turnover. In chronic renal failure, the CtBP2-p300-AP1 transcriptional complex upregulates TGF-beta expression, increasing ligand availability for binding.
transforming growth factor beta binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR2 | Colorectal cancer, fibrosis | Knockout in HCT116 cells; point mutation to mimic kinase-dead receptor |
| LTBP4 | Muscular dystrophy, fibrosis | Knockout mouse; overexpression in fibroblasts |
| DCN | Fibrosis, corneal dystrophy | Overexpression in renal mesangial cells; KO in mouse |
| THBS1 | Wound healing defects, cancer | KO mouse; knock-in of thrombospondin-1 variants |
| ITGB6 | Pulmonary fibrosis, cancer | KO mouse; point mutation in integrin binding site |
TGF-beta binding in fibrosis and chronic renal failure
Increased TGF-beta binding to receptors and matrix proteins drives fibrotic responses in kidney, lung, and skin. In chronic renal failure, the CtBP2-p300-AP1 complex activates TGF-beta transcription, leading to enhanced binding and downstream SMAD signaling that promotes extracellular matrix deposition. Targeting TGF-beta binding with inhibitors or CRISPR-mediated knockout of receptors reduces fibrosis in preclinical models.
TGF-beta binding in cancer
TGF-beta binding can have dual roles in cancer: in early stages, it inhibits proliferation, but in advanced stages, it promotes invasion and metastasis. Mutations in TGFBR2 or SMAD4 that impair TGF-beta binding are common in colorectal and pancreatic cancers. Therapeutic strategies aim to block TGF-beta binding to its receptors to reduce tumor progression.
TGF-beta binding in wound healing and tissue repair
During skin wound healing, TGF-beta binding to receptors on fibroblasts and myofibroblasts stimulates collagen production and contractility. In mice lacking hyaluronan synthases 1 and 3, enhanced TGF-beta receptor-mediated p38 MAPK signaling drives myofibroblast differentiation, highlighting the importance of binding in repair. Dysregulated binding can lead to hypertrophic scars or chronic wounds.
From transforming growth factor beta binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFBR2 abolish TGF-beta binding? | CRISPR knockout of TGFBR2 in HEK293 or fibroblasts |
| How does a point mutation in TGFBR1 affect ligand affinity? | CRISPR point mutation (e.g., kinase domain) followed by binding assays |
| Can a tagged TGFBR2 be used to track binding dynamics? | Knock-in of fluorescent tag (e.g., GFP) at endogenous locus |
| Does overexpression of decorin reduce TGF-beta binding to receptors? | Overexpression of DCN in fibrotic cell models |
| Which genes regulate latent TGF-beta activation? | CRISPR library screening targeting LTBP and integrin genes |
| Does a disease-associated SNP in LTBP4 alter binding? | Knock-in of the SNP in mouse models |
How to Study the transforming growth factor beta binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics (kon, koff, Kd) | Characterize TGF-beta binding to purified receptors |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Validate binding stoichiometry |
| Luciferase reporter assay | SMAD transcriptional activity | Measure functional consequences of binding |
| Phospho-SMAD immunoblot | Activation of downstream signaling | Confirm receptor activation after binding |
| Affinity purification-mass spectrometry | Protein-protein interactions | Identify novel TGF-beta binding partners |
| Proximity ligation assay (PLA) | In situ binding events | Visualize TGF-beta binding in fixed cells |
| TIRF microscopy | Real-time binding at cell surface | Study receptor clustering and dynamics |
| FRET biosensor | Conformational changes upon binding | Live-cell monitoring of TGF-beta binding |
Biochemical binding assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) measure the affinity and kinetics of TGF-beta binding to receptors or proteoglycans. These methods provide quantitative data on dissociation constants (Kd) and are used to validate CRISPR-engineered mutations.
Cell-based signaling assays
Luciferase reporter assays driven by SMAD-responsive elements measure TGF-beta binding-induced transcriptional activity. Phospho-SMAD immunoblotting quantifies downstream signaling after ligand binding. These assays are often used with CRISPR knockout cells to confirm loss of binding.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry (AP-MS) identifies novel TGF-beta binding proteins. Proximity ligation assays (PLA) can visualize binding events in situ. These approaches help map the TGF-beta interactome.
Imaging and live-cell tracking
Total internal reflection fluorescence (TIRF) microscopy and fluorescence resonance energy transfer (FRET) sensors enable real-time visualization of TGF-beta binding to receptors on the cell surface. These techniques reveal binding dynamics and receptor clustering.
How CRISPR Can Be Used to Study GO:0050431 transforming growth factor beta binding
Knockout
CRISPR knockout of genes encoding TGF-beta receptors (TGFBR1, TGFBR2) or binding proteins (LTBP1, DCN) abolishes or reduces TGF-beta binding, enabling studies of downstream signaling and disease phenotypes. Knockout cell lines are used to confirm specificity of binding inhibitors.
Point Mutation
CRISPR point mutations can mimic disease-associated variants in TGFBR2 or LTBP4, altering binding affinity or specificity. These models help dissect the structural determinants of TGF-beta binding and validate drug targets.
Knock-in
Knock-in of epitope tags (e.g., HA, GFP) or fluorescent proteins at endogenous loci allows tracking of TGF-beta binding proteins in live cells. Knock-in of reporter genes under TGF-beta-responsive promoters enables quantification of binding-induced signaling.
Overexpression
CRISPR-mediated overexpression of decorin or other TGF-beta binding proteoglycans can sequester TGF-beta and reduce signaling, offering a strategy to counteract fibrosis. Overexpression of TGFBR3 (betaglycan) enhances ligand presentation and signaling in some contexts.
How EDITGENE Supports transforming growth factor beta binding Research
Researchers studying transforming growth factor beta binding-related genes often need to determine whether a candidate gene is causally involved in ligand binding, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta binding research.
Frequently Asked Questions About transforming growth factor beta binding
What is GO:0050431?
GO:0050431 is the Gene Ontology molecular function term for transforming growth factor beta binding, defined as binding to TGF-beta, a multifunctional peptide that controls proliferation, differentiation and other functions in many cell types.
What genes are involved in transforming growth factor beta binding?
Key genes include TGFBR1, TGFBR2, TGFBR3, LTBP1-4, DCN, BGN, THBS1, ITGB6, and ITGB8, which encode receptors, latent binding proteins, and proteoglycans that interact with TGF-beta.
How does TGF-beta binding activate signaling?
TGF-beta binds to TGFBR2, which recruits and phosphorylates TGFBR1, leading to SMAD2/3 phosphorylation and transcriptional regulation.
What diseases are associated with abnormal TGF-beta binding?
Dysregulated TGF-beta binding is linked to fibrosis, chronic renal failure, cancer, and connective tissue disorders.
What are the synonyms for GO:0050431?
Synonyms include TGF-beta binding, TGFbeta binding, transforming growth factor beta ligand binding to type II receptor, and transforming growth factor beta ligand binding to type I receptor.
How can I study TGF-beta binding using CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes encoding TGF-beta binding proteins to study binding affinity and downstream effects.
What methods measure TGF-beta binding affinity?
Surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and cell-based assays such as luciferase reporters and phospho-SMAD immunoblotting are commonly used.
What is the role of latent TGF-beta binding proteins?
LTBPs covalently bind latent TGF-beta, sequestering it in the extracellular matrix until activation by thrombospondin-1 or integrins.
Can decorin inhibit TGF-beta binding?
Yes, decorin binds TGF-beta and neutralizes its activity, reducing fibrosis in preclinical models.
How does TGF-beta binding contribute to wound healing?
TGF-beta binding to receptors on fibroblasts stimulates collagen production and myofibroblast differentiation, which are essential for wound closure.
Conclusion
GO:0050431, transforming growth factor beta binding, is a fundamental molecular function that initiates a wide array of cellular responses. Its precise regulation is critical for normal development and tissue homeostasis, while its dysregulation underlies fibrosis, cancer, and chronic kidney disease. Advances in CRISPR-based models and biochemical assays continue to unravel the complexities of TGF-beta binding, offering new opportunities for therapeutic intervention. EDITGENE's comprehensive services empower researchers to dissect this pathway with high precision and reproducibility.
References
- 1. Li Y et al.. 2022. Transforming growth factor-β signalling pathway in tendon healing.. Growth Factors 40(3-4):98-107 PMID: 35707986
- 2. Boyd FT et al.. 1990. Transforming growth factor-beta receptors and binding proteoglycans.. J Cell Sci Suppl 13:131-8 PMID: 1964683
- 3. Shi Y et al.. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus.. Cell 113(6):685-700 PMID: 12809600
- 4. Miyazono K et al.. 1993. Transforming growth factor-beta: latent forms, binding proteins and receptors.. Growth Factors 8(1):11-22 PMID: 8383513
- 5. Zhou P et al.. 2020. Transforming growth factor beta (TGF-β) is activated by the CtBP2-p300-AP1 transcriptional complex in chronic renal failure.. Int J Biol Sci 16(2):204-215 PMID: 31929749
- 6. Teicher BA. 2021. TGFβ-Directed Therapeutics: 2020.. Pharmacol Ther 217:107666 PMID: 32835827
- 7. Murphy-Ullrich JE et al.. 1992. Transforming growth factor-beta complexes with thrombospondin.. Mol Biol Cell 3(2):181-8 PMID: 1550960
- 8. Wang Y et al.. 2022. Transforming Growth Factor-β Receptor-Mediated, p38 Mitogen-Activated Protein Kinase-Dependent Signaling Drives Enhanced Myofibroblast Differentiation during Skin Wound Healing in Mice Lacking Hyaluronan Synthases 1 and 3.. Am J Pathol 192(12):1683-1698 PMID: 36063901
